Pliant Therapeutics Inc Ordinary Shares PLRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 61.92M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- https://www.pliantrx.com
Valuation
|
Metric
|
PLRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.43 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PLRX
Financial Strength
|
Metric
|
PLRX
|
|---|---|
Quick Ratio | 16.59 |
Current Ratio | 16.89 |
Interest Coverage | −68.77 |
Quick Ratio
PLRX
Profitability
|
Metric
|
PLRX
|
|---|---|
Return on Assets (Normalized) | −33.29% |
Return on Equity (Normalized) | −43.86% |
Return on Invested Capital (Normalized) | −38.68% |
Return on Assets
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>Y%H@w@ | LOCK|R&RT | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|G<!w$j | LOCK|tj@hm | $71B | |||
| argenx SE ADR
ARGX
| LOCK|ht%@p& | LOCK|>G | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@RfP<S | LOCK|H?k | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$H@zWxy | LOCK|DF$# | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Tt?>KK$ | LOCK|zND& | $26B | |||
| Moderna Inc
MRNA
| LOCK|Z$%$M& | LOCK|RT | $25B | |||
| Incyte Corp
INCY
| LOCK|!#BbV&k | LOCK|%<F | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>t^Bzw$ | LOCK|yY | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&Hfp<?W | LOCK|M>! | $16B |
United States